{"id":7401,"date":"2025-06-25T16:58:56","date_gmt":"2025-06-25T13:58:56","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7401"},"modified":"2025-06-25T16:58:56","modified_gmt":"2025-06-25T13:58:56","slug":"lower-blood-pressure-targets-in-type-2-diabetes-june-2025-medscape","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/lower-blood-pressure-targets-in-type-2-diabetes-june-2025-medscape\/","title":{"rendered":"Lower Blood Pressure Targets in Type 2 Diabetes (June 2025). Medscape."},"content":{"rendered":"
Lower Blood Pressure Targets in Type 2 Diabetes (June 2025). Medscape.<\/div>\n
<\/div>\n
1. Study Overview<\/span><\/div>\n
\u2022 Large randomized trial conducted in China with over 12,000 patients >50 years old, all with type 2 diabetes and high cardiovascular risk.<\/span><\/div>\n
\u2022 Aim: Compare intensive systolic BP control (<120 mmHg) vs standard control (<140 mmHg).<\/span><\/div>\n
2. Primary Outcomes Tracked<\/span><\/div>\n
\u2022 Nonfatal stroke<\/span><\/div>\n
\u2022 Nonfatal myocardial infarction (MI)<\/span><\/div>\n
\u2022 Hospitalization for heart failure<\/span><\/div>\n
\u2022 Cardiovascular death<\/span><\/div>\n
3. Key Results<\/span><\/div>\n
\u2022 Mean follow-up: ~4 years<\/span><\/div>\n
\u2022 Significant reduction in primary cardiovascular outcomes in the intensive group.<\/span><\/div>\n
\u2022 Outcomes began to diverge after about 1 year of treatment.<\/span><\/div>\n
4. Blood Pressure Findings<\/span><\/div>\n
\u2022 Mean BP achieved:<\/span><\/div>\n
\u2022 Intensive group: 121.6 mmHg<\/span><\/div>\n
\u2022 Standard group: 133.2 mmHg<\/span><\/div>\n
\u2022 Difference (~12 mmHg) was associated with clear outcome benefit.<\/span><\/div>\n
5. Study Design Highlights<\/span><\/div>\n
\u2022 BP measured using standardized protocol:<\/span><\/div>\n
\u2022 No caffeine, smoking, or exercise 30 mins prior<\/span><\/div>\n
\u2022 5-minute rest<\/span><\/div>\n
\u2022 3 silent readings, 1 minute apart<\/span><\/div>\n
\u2022 Average of 3 readings used to guide treatment.<\/span><\/div>\n
6. Medication Use & Safety<\/span><\/div>\n
\u2022 Intensive group required 1\u20132 more medications on average.<\/span><\/div>\n
\u2022 No major difference in serious adverse events.<\/span><\/div>\n
\u2022 Increased rates of symptomatic hypotension and hyperkalemia in intensive group.<\/span><\/div>\n
7. Clinical Implication<\/span><\/div>\n
\u2022 The author (Dr. Anne Peters) notes this has changed her practice, now targeting systolic BP closer to 120 mmHg for eligible patients.<\/span><\/div>\n
\u2022 Suggests tighter BP control may lead to better cardiovascular protection, if tolerated.<\/span><\/div>\n
8. Conclusion<\/span><\/div>\n
\u2022 The trial may influence future guidelines.<\/span><\/div>\n
\u2022 Lowering systolic BP below 130 mmHg\u2014and ideally closer to 120\u2014could provide added benefit for patients with type 2 diabetes and high CV risk.<\/span><\/div>\n
https:\/\/click.mail.medscape.com\/?qs=76fadc4076152fbedbc2f27373406115d09da2f22d29e6342e1d9aaaba8e5c2cfa7c21ef37e64768f7a7911ba58bea3542173207a6ddbefa5bfeb2b05fec0d9a<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Lower Blood Pressure Targets in Type 2 Diabetes (June 2025). Medscape. 1. Study Overview \u2022 Large randomized trial conducted in China with over 12,000 patients >50 years old, all with type 2 diabetes and high cardiovascular risk. \u2022 Aim: Compare intensive systolic BP control (<120 mmHg) vs standard control (<140 mmHg). 2. Primary Outcomes Tracked […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7401","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7401"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7401\/revisions"}],"predecessor-version":[{"id":7410,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7401\/revisions\/7410"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}